Loading
KB
Kiromic Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BERSANI PIETRO, was filed 26 Aug 2024.
Kiromic Biopharma, Inc.: what insiders have been doing
This page follows insider dealings at Kiromic Biopharma, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Kiromic Biopharma, Inc. has had no insider filing for more than a year; the last one goes back to 26 August 2024.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
21
Thresholds
n/a
Buy Volume
€73,112
11 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$23.2M
Last declaration on 26 August 2024
Declarations21 total
2,500 shares@ US$2.2035.4% of flowCommon StockSEC:0001437749-24-027784:0
Canonical exit: 21 Nov 2024 (T+90)
258 shares@ US$2.255.8% of flowCommon StockSEC:0001437749-24-027492:0
Canonical exit: 17 Nov 2024 (T+90)
2,000 shares@ US$1.7535.1% of flowCommon StockSEC:0001437749-24-026863:0
Canonical exit: 11 Nov 2024 (T+90)
1,200 shares@ US$3.3044.2% of flowCommon StockSEC:0001104659-24-071382:0
Canonical exit: 10 Sept 2024 (T+90)
1,000 shares@ US$2.6026.7% of flowCommon StockSEC:0001104659-24-071297:0
Canonical exit: 11 Sept 2024 (T+90)
1,000 shares@ US$3.33100.0% of flowCommon StockSEC:0001104659-24-070884:0
Canonical exit: 9 Sept 2024 (T+90)
3,000 shares@ US$3.2364.6% of flowCommon StockSEC:0001104659-24-070880:0
Canonical exit: 9 Sept 2024 (T+90)
1,000 shares@ US$3.1832.4% of flowCommon StockSEC:0001104659-24-070881:0
Canonical exit: 10 Sept 2024 (T+90)
1,701 shares@ US$2.9355.8% of flowCommon StockSEC:0001104659-24-070883:0
Canonical exit: 8 Sept 2024 (T+90)
45,968 shares0Restricted Stock AwardSEC:0001104659-24-058091:0
35,033 shares0Restricted Stock AwardSEC:0001104659-24-058167:0
18,000 sharesRestricted Stock AwardSEC:0001104659-24-036801:0
18,000 sharesRestricted Stock AwardSEC:0001104659-24-036806:0
18,000 sharesRestricted Stock AwardSEC:0001104659-24-036804:0
638,298 shares0Common StockSEC:0001104659-22-091234:0
50,000 shares0Common StockSEC:0001104659-22-091237:0
50,000 shares0Common StockSEC:0001104659-22-091245:0
17,240 sharesCommon StockSEC:0001104659-22-064646:0
2,800 shares@ US$3.699100.0% of flowCommon StockSEC:0001104659-21-114510:0
Canonical exit: 8 Dec 2021 (T+90)
50,189 shares0Common StockSEC:0001104659-21-098784:0
5,000 shares@ US$7.31100.0% of flowCommon StockSEC:0001104659-21-072372:0
Canonical exit: 22 Aug 2021 (T+90)
21 of 21 declarations
About Kiromic Biopharma, Inc.
Kiromic Biopharma, Inc. (ticker: KRBP) is a U.S.-listed clinical-stage biopharmaceutical company traded on the NASDAQ (United States), focused on precision oncology and cell therapy. Founded in 2016 and headquartered in Houston, Texas, the company built its strategy around combining artificial intelligence, data mining, and biopharma development to identify therapeutic targets and advance immuno-oncology programs. Kiromic originally operated with a discovery-led model and later evolved into a more integrated organization spanning target identification, product development, and manufacturing preparation. Its Houston base gives it proximity to a major medical and research ecosystem, which is important for clinical collaboration and operational execution.
The company’s core platform is DIAMOND®, its proprietary AI-driven target discovery engine. Using that platform, Kiromic has been developing cell and gene therapies with a strong emphasis on solid-tumor immunotherapy. Its lead program is Deltacel™, an allogeneic gamma delta T-cell therapy derived from donors and designed for solid cancers, with an initial clinical focus on metastatic non-small cell lung cancer (NSCLC). The company has also referenced other oncology programs, but Deltacel and the gamma delta T-cell platform are the main assets shaping its public investment profile today.
Read moreShow less
From a competitive standpoint, Kiromic occupies a niche position relative to better-capitalized biotech peers. Its differentiation lies in two elements: an AI-based discovery workflow intended to accelerate target selection, and an allogeneic approach that could offer better scalability than some autologous cell therapies. That said, KRBP remains a highly speculative small-cap development company with substantial risks tied to clinical execution, regulatory approvals, capital access, and manufacturing scale-up. Investors should also note the company’s regulatory history: in 2024, the SEC announced settled charges related to undisclosed FDA review status issues, which is relevant when assessing governance quality and disclosure risk.
Recent milestones include FDA Fast Track designation for Deltacel in 2024 and continued progress in the Deltacel-01 Phase 1 trial, including additional clinical site activation and early signs of tumor reduction reported in an initial patient. In 2025, the company also raised capital through a senior secured convertible note, reinforcing that liquidity and financing remain important themes. For French-speaking investors, KRBP should be viewed as a high-risk, event-driven biotechnology name listed on NASDAQ in the United States, where future value creation depends primarily on clinical validation of Deltacel, continued funding of trials, and disciplined regulatory execution.
